ATE322684T1 - Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung - Google Patents

Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung

Info

Publication number
ATE322684T1
ATE322684T1 AT95927423T AT95927423T ATE322684T1 AT E322684 T1 ATE322684 T1 AT E322684T1 AT 95927423 T AT95927423 T AT 95927423T AT 95927423 T AT95927423 T AT 95927423T AT E322684 T1 ATE322684 T1 AT E322684T1
Authority
AT
Austria
Prior art keywords
peptides
amino acid
acid residues
src
binding affinities
Prior art date
Application number
AT95927423T
Other languages
English (en)
Inventor
Andrew B Sparks
Brian K Kay
Judith M Thorn
Lawrence A Quilliam
Channing J Der
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/278,865 external-priority patent/US6303574B1/en
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE322684T1 publication Critical patent/ATE322684T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95927423T 1994-07-22 1995-07-24 Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung ATE322684T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/278,865 US6303574B1 (en) 1994-07-22 1994-07-22 Scr SH3 binding peptides and methods of isolating and using same
US48355595A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE322684T1 true ATE322684T1 (de) 2006-04-15

Family

ID=26959309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927423T ATE322684T1 (de) 1994-07-22 1995-07-24 Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung

Country Status (7)

Country Link
EP (1) EP0772773B1 (de)
JP (2) JP4215274B2 (de)
AT (1) ATE322684T1 (de)
AU (1) AU3146095A (de)
CA (1) CA2195629A1 (de)
DE (1) DE69534920T2 (de)
WO (1) WO1996003649A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804218A1 (de) * 1994-03-17 1997-11-05 National Jewish Center For Immunology And Respiratory Medicine Produkt und Verfahren zur Regulierung von Signalübertragungswegen
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
WO1996031625A1 (en) * 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
WO1998017301A1 (en) * 1996-10-21 1998-04-30 Howard Mark E Peptides for inhibiting retroviruses
AU6820998A (en) 1997-04-07 1998-10-30 Bioimage A/S A method for extracting quantitative information relating to an influence on a cellular response
IT1291110B1 (it) * 1997-04-15 1998-12-29 Istituto Europ Di Oncologia S Interattori intracellulari e specificita' di legame del dominio eh
GB9711148D0 (en) * 1997-05-31 1997-07-23 Peptide Therapeutics Ltd Human MAFA
EP1121593A2 (de) * 1998-10-15 2001-08-08 BioImage A/S Verfahren zur ableitung quantitativer informationen über einen einfluss auf eine zelluläre respons
CA2374180C (en) * 1999-05-26 2012-09-11 Marita Hiipakka Methods and materials for generating sh3 domains with tailored binding properties
EP2752196A1 (de) * 2013-01-03 2014-07-09 Université Bordeaux Segalen Selektive NOX-1-Hemmerpeptide und Verwendungen davon
US10161938B2 (en) 2013-12-27 2018-12-25 Roche Sequencing Solutions, Inc. Systematic discovery, maturation and extension of peptide binders to proteins
JP2018513166A (ja) 2015-04-20 2018-05-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 系統的な探索、成熟化および伸長プロセスにより同定した、タンパク質に対する特異的ペプチドバインダー
CN106589062B (zh) * 2016-12-09 2020-03-24 上海市第一妇婴保健院 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用
EP3579853A1 (de) 2017-02-13 2019-12-18 Biocontrol Limited Therapeutische bakteriophagenzusammensetzungen
CA3087338A1 (en) * 2018-01-02 2019-07-11 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions for treating staphylococcus infection
EP3757217A1 (de) * 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Verfahren zur proteinaufreinigung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2159895A (en) * 1994-03-11 1995-09-25 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains

Also Published As

Publication number Publication date
EP0772773B1 (de) 2006-04-05
EP0772773A1 (de) 1997-05-14
JP4215274B2 (ja) 2009-01-28
CA2195629A1 (en) 1996-02-08
JP2007259856A (ja) 2007-10-11
WO1996003649A1 (en) 1996-02-08
DE69534920D1 (de) 2006-05-18
DE69534920T2 (de) 2007-04-05
JPH10503369A (ja) 1998-03-31
AU3146095A (en) 1996-02-22
EP0772773A4 (de) 1999-08-11

Similar Documents

Publication Publication Date Title
EP1538157A3 (de) Sh3-bindender Peptide und deren Verwendung
ATE322684T1 (de) Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung
Krumpe et al. T7 lytic phage‐displayed peptide libraries exhibit less sequence bias than M13 filamentous phage‐displayed peptide libraries
IL131435A0 (en) In vitro peptide or protein expression library
WO2000068263A3 (en) Stereoselective antifibrillogenic peptides and peptidomimetics thereof
HU9201687D0 (en) Preparation of sets from peptid mixtures with polycomponents and their use for the identification of biologically active peptides
AU2845495A (en) Random bio-oligomer libraries
AU2001268173A1 (en) Microarrays for performing proteomic analyses
Atlas The active site of porcine elastase
CA2302147A1 (en) Methods for protein screening
GB9722320D0 (en) Human cell cycle checkpoint proteins
WO2004069200A3 (en) Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
WO1996013592A3 (en) Protein kinase npk-110
WO1997012039A3 (en) Sh2-containing inositol-phosphatase
WO1996035715A3 (en) Pcna binding substance
GB9816514D0 (en) Novel method
WO2002026783A3 (en) Chimeric retroviral gag genes and screening assays
DE69504795D1 (de) Methoden zur synthese und reinigung von peptiden
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier
Bremnes et al. Selection of phage displayed peptides from a random 10-mer library recognising a peptide target
Harfst et al. A comparative analysis of the phosphorylation and biochemical properties of wild type and host range variant DNA binding proteins of human adenovirus 5
Coulon et al. Cyclic peptides selected by phage display mimic the natural epitope recognized by a monoclonal anti‐colicin A antibody
Herwig et al. Cross-linked amino acids in the protein pairs L3-L19 and L23-L29 of Bacillus stearothermophilus ribosomes after treatment with diepoxybutane.
WO2001027269A3 (en) Vip54 protein and related materials
EP0331184A3 (de) Peptid-Gegenwerte von Nichtpeptiden und Verfahren zum Entwurf dafür

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties